- In March 2024, Sanofi announced the initiation of a Phase II clinical trial evaluating the efficacy of a new topical immunomodulator specifically targeting severe cases of Nodular Prurigo. The novel formulation aims to reduce lesion formation and chronic itch in patients unresponsive to corticosteroids, showcasing the company's dedication to addressing underserved dermatological conditions. This move reinforces Sanofi’s commitment to expanding its dermatology pipeline and delivering innovative treatment options for chronic pruritic diseases
- In February 2024, VYNE Therapeutics Inc. received orphan drug designation from the U.S. FDA for its investigational drug candidate VYN201, aimed at treating moderate to severe Nodular Prurigo. The compound, which leverages pan-BET inhibitor technology, is designed to modulate inflammatory pathways implicated in chronic pruritus. This development marks a significant milestone in VYNE's strategy to address high-burden dermatological diseases with limited therapeutic options
- In January 2024, Trevi Therapeutics presented positive interim results from its Phase II study of Haduvio (nalbuphine ER) in patients with severe itch associated with Nodular Prurigo. The findings indicated substantial reductions in pruritus intensity and sleep disruption scores, highlighting Haduvio’s potential as a novel oral therapy. The company intends to advance into a pivotal Phase III trial later in the year to further evaluate efficacy and safety
- In December 2023, GSK plc announced a strategic collaboration with a leading dermatology research institute in Europe to develop biologic therapies targeting neuroimmune pathways involved in chronic prurigo diseases, including Nodular Prurigo. The partnership focuses on monoclonal antibodies that address both inflammation and neural sensitization, aiming to provide long-term symptom control for patients
- In November 2023, Galderma Laboratories, L.P. expanded its dermatology portfolio with the launch of a prescription-grade capsaicin cream for refractory Nodular Prurigo cases. This product leverages a patented delivery system to reduce skin irritation commonly associated with topical capsaicin, making it more tolerable for long-term use. The launch aligns with Galderma’s goal to offer innovative, patient-friendly treatment options in chronic inflammatory skin conditions
